Trauma Innovation


Trauma Innovation

Defence medicine remains at the forefront of Trauma Innovation, continuing in prevention and treatment of critical injury, with proven exceptional outcomes on recent campaigns. However, the tempo of campaigns has slowed down, but this has not affected the UK Defence Medical Services from continuing its extensive research into conflict medicine.   Trauma Innovation 2017 looks at how we can think outside the box, and translate interventions /lessons learnt into the far forward environment and to implement early into military care those active areas of research where military and civilian emergency care medicine continue to develop ground breaking research.

Technologies and Treatment

There is a predisposition to limit all medical interventions to locations where there are optimal facilities, and an abundance of resources.  Unfortunately, conflict and humanitarian operations rarely have this luxury. This conference will look at the immediate horizon to establish what technologies and treatment modalities are available and are we able to break the mould of conventional thinking and apply these in a different location or different clinical context.

Delegates can expect to interact with an internationally renowned faculty, all of whom are world leaders in their discipline.

Primary Themes

Future Far Forward Interventions

To optimally care for patients, it is vital to have a sound understanding of the relevant disease process.  The same can be stated for trauma; it is vital to understand wounding mechanisms so that we can pre-emptively mitigate against the injury occurring, and if injury has occurred to provide the optimum modality to treat.

Haemorrhage Cessation

Optimum care should not be limited by geography, and in some cases lifesaving care must be given at the point of wounding.  This session looks to the near future, where novel technologies and changes in mentality will allow for prevention of injury or earlier interventions.

Future of Military Trauma Care

The debate about the optimal blood product resuscitative strategy continues.  Current evidence will be evaluated in the management of coagulopathy and trauma in a severely injured with a look towards future trauma innovations/haemostatic resuscitation and physiological suspended animation.

Disrupting the Coagulopathy

Tranexamic Acid remains an important topic of discussion.  Professor Ian Roberts is the principal investigator of the CRASH trials which have shaped the management of trauma coagulopathy.  His current focus is the conduct of large scale trials of tranexamic acid in the management of acute severe bleeding.

Trauma Innovation 2016


Sponsors & Partners


Ministry of DefenceDepartment for International TradeDefence & Security OrganisationADS



General Enquiries / +44 (0)20 7384 7770

Contact Info